GNTA - Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach

• H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science ( NASDAQ: GNTA ) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer.
• The firm has a $25 price target (269% upside based on Friday's close).
• Genenta shares are down 9% in early Monday afternoon tradig.
• Analyst Emanuela Branchetti said that the company's technology is "based on the ex-vivo lentiviral vector (LVV) mediated modification of autologous hematopoietic stem/progenitor cells (HSPCs) that deliver immunomodulatory molecules directly to the tumor."
• She highlighted four advantages/differentiating factors of Genenta's ( GNTA ) tech: 1. It focuses on a type tumor-associated myeloid cells (TEMs) that known to be involved in promoting angiogenesis and tumor growth; 2. It is built in a way that controls transgene expression and avoids off-target and systemic toxicity; 3. It has potential for long-tern durabiklity given the use of HSPCs; and 4) It is agnostic so it could potentially be used in a wide variety of cancers.
• Genenta's ( GNTA ) lead candidate, temferon, is currently in phase 1/2a for glioblastoma multiforme. It is idesigned to deliver IFN-? only at the tumor site.
• A data update is expected in this half of the year with enrollment completion in H1 2023. A phase 2 study is planned for H2 2023.

For further details see: